Starpharma has developed an innovative proprietary dendrimer called SPL7013, which has a novel mechanism of action and anti-infective properties. Starpharma has developed and launched three innovative products containing SPL7013 in various international markets.

Starpharma’s marketed SPL7013 product range includes a broad-spectrum nasal spray for cold/respiratory viruses, a non-antibiotic vaginal gel for the treatment of bacterial vaginosis (BV) and prevention of recurrent BV, and an antiviral condom.

Starpharma's VIRALEZE™ Nasal Spray is a broad-spectrum nasal spray intended to provide a protective barrier in the nose that traps and blocks cold/respiratory viruses. The nasal spray contains SPL7013, which has been shown in clinical, nonclinical, and laboratory studies to trap and block a broad spectrum of cold/respiratory viruses, helping to prevent their adhesion, multiplication and spread.

VIRALEZE™ is registered in more than 35 countries and has been commercialised in a number of markets, including the UK, Europe, and Asia. Brand name and product claims may differ by market.

VIRALEZE™ is not approved for use or supply in Australia.

Starpharma’s VivaGel® Condom is an antiviral condom. The condom lubricant contains SPL7013, which is an antiviral agent proven, in laboratory studies only, to inactivate HIV, herpes simplex virus (HSV) and human papillomavirus (HPV), which are viruses that cause STIs. The VivaGel® Condom has been commercialised in a number of markets, including Japan. Brand name and product claims may differ by market.